A double-blind study of the efficacy of apomorphine and its assessment in "off-periods in Parkinson's disease [PDF]
, 1993 Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected for a randomized double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment in `off¿-periods. The
Essink, A.W.G. +4 more
core +6 more sources
Clinical Parkinsonism & Related Disorders, 2023 Introduction: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment.
Stuart H. Isaacson +3 more
doaj +1 more source
Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population
Annals of Movement Disorders, 2020 Although subcutaneously administered apomorphine is widely used as an effective adjunct therapy for Parkinson’s disease (PD), it was approved for use in India only in 2019. This review summarizes the history, pharmacology, clinical spectrum, indications,
Vinod Metta +7 more
doaj +1 more source
Motor Evoked Potentials Improve Targeting in Deep Brain Stimulation Surgery
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Objectives One of the main challenges posed by the surgical deep brain stimulation (DBS) procedure is the successful targeting of the structures of interest and avoidance of side effects, especially in asleep surgery. Here, intraoperative motor evoked potentials (MEPs) might serve as tool to identify the pyramidal tract.
Petyo Nikolov +7 more
wiley +1 more source
Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish
Frontiers in Neuroscience, 2022 Ankyrin repeat and kinase domain containing 1 (ANKK1) is a member of the receptor-interacting protein serine/threonine kinase family, known to be involved in cell proliferation, differentiation and activation of transcription factors.
Adele Leggieri +9 more
doaj +1 more source
MCH and apomorphine in combination enhance action potential firing of nucleus accumbens shell neurons in vitro [PDF]
PeerJ, 2013 The MCH and dopamine receptor systems have been shown to modulate a number of behaviors related to reward processing, addiction, and neuropsychiatric conditions such as schizophrenia and depression. In addition, MCH and dopamine receptors can interact in
F Woodward Hopf +3 more
doaj +2 more sources
Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Asian Journal of Pharmaceutical Sciences, 2018 Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss.
Nrupa Borkar, Huiling Mu, René Holm
doaj +1 more source
The Influence of Hyperactivity of the Hypothalamic-pituitary-adrenal Axis and Hyperglycemia on the 5-HT2A Receptor-mediated Wet-dog Shake Responses in Rats [PDF]
, 2007 Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis induces hyperglycemia and serotonin (5-HT)2A receptor supersensitivity. In the present study, to investigate the effect of hyperglycemia on the function of 5-HT2A receptors, we compared the 5-
Amano, Manabu +7 more
core +1 more source
Apomorphine: The initial indian experience in relation to response tests and pumps
Annals of Indian Academy of Neurology, 2020 Background: Apomorphine is an option for continuous dopaminergic therapy in Parkinson's disease (PD). However, its effects in varied populations are limited due to its availability.
L K Prashanth +3 more
doaj +1 more source